Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
This is an online, on-demand video program designed to deliver concise, modular education. In these modules, Erin D. Michos, MD, MHS, and Nihar Desai, MD, MPH, discuss the correlation between lipids and the risk of ASCVD, and review current and emerging therapies to reduce LDL. Several case studies will be presented to illustrate how patients with dyslipidemia can be effectively managed, with expert faculty providing clinical pearls along the way.
Target Audience
This educational activity is directed toward cardiologists, family medicine physicians, specialty NPs, PAs, RNs and other HCPS involved in the care of dyslipidemia.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the distinct lipid metabolism pathways targeted by lipid-lowering agents
- Analyze the safety and efficacy data of newer lipid-lowering therapies in patients who have not achieved lipid-management goals with statins
- Apply evidence-based strategies to individualize lipid-lowering treatment plans for patients with persistent low-density lipoprotein cholesterol (LDL-C) elevation
- Formulate actionable solutions to optimize the utilization of non-statin treatments in clinical practice for the management of dyslipidemia and/or atherosclerotic cardiovascular disease (ASCVD)
Erin D. Michos, MD, MHS
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Astrazeneca, Arrowhead, Bayer, Boehringer Ingelheim, Edwards Lifescience, Eli Lilly, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer
Nihar Desai, MD, MPH
Associate Professor of Cardiovascular Medicine
New Haven, CT
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Arrowhead, Bayer Healthcare Pharmaceuticals, Merck, Milestone, Vifor Research Grants: Amgen, Astra Zeneca, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Cytokinetics, Novartis Corporation, Relypsa, SC Pharmaceuticals
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here